Legend Biotech's CARVYKTI Shows 50% Five-Year Progression-Free…

Event summary

Legend Biotech presented five-year data from CARTITUDE-2 Cohort A showing 50% of patients with relapsed/refractory multiple myeloma (RRMM) remained progression-free and alive after a single CARVYKTI infusion.
The study involved 20 patients with a median follow-up of 60.7 months, reinforcing CARVYKTI's potential as a curative treatment in earlier-line RRMM.
Overall survival rate was 69.2%, with no new CAR T-cell-related neurotoxicity reported during extended follow-up.
CARVYKTI is a BCMA-directed autologous T-cell immunotherapy developed in collaboration with Janssen Biotech, a Johnson & Johnson company.

The big picture

Legend Biotech's data underscores the growing evidence supporting CARVYKTI's curative potential in earlier-stage multiple myeloma, a strategic advantage in the competitive cell therapy landscape. The results position CARVYKTI as a potential standard of care, potentially reshaping treatment paradigms for this incurable blood cancer. With over 3,000 employees and a global footprint, Legend Biotech is well-positioned to capitalize on these findings to drive further innovation in cell therapy.

What we're watching

Market Positioning: Whether Legend Biotech can leverage these long-term data to expand CARVYKTI's market share in earlier-line RRMM treatments.
Regulatory Approvals: The pace at which regulatory bodies approve CARVYKTI for broader indications based on these extended efficacy results.
Competitive Dynamics: How rival cell therapies will respond to CARVYKTI's demonstrated durability in treating multiple myeloma.